LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q1 2022 Earnings Conference Call April 28, 2022 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Zach Weiner - Jefferies Brooks O’Neil - Lake Street Capital Mike Petusky - Barrington Research Jim Sidoti - Sidoti Javier Fonseca - Spartan Capital Operator Welcome to the LeMaitre Vascular Q1 2022 Financial Results Conference Call. As a remin ...

LeMaitre Vascular, Inc. Investor Presentation 1 Disclaimers Unaudited Quarterly & 2021 Financial Results The quarterly and 2021 financial results in this document are unaudited. Forward-Looking Statements This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward-looking statements. Factors that ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☑ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State o ...

Financial Data and Key Metrics Changes - Q4 2021 sales increased by 5% to $39.5 million, with a 19% increase in total sales for 2021 to $154.4 million compared to 2020 [8][15] - Operating income for Q4 2021 was $8.3 million, a decrease of 13% year-over-year, while net income and operating income both grew by 27% for the full year 2021 [17][16] - Gross margin for Q4 2021 was 65.7%, a 70 basis point increase from Q4 2020, driven by average selling price increases and favorable sales mix [17] Business Line Data and Key Metrics Changes - Artegraft sales grew by 16% year-over-year to $6.4 million, contributing significantly to Q4 sales growth [8] - Biologics accounted for 48% of sales in the quarter, with a 10% increase [33] Market Data and Key Metrics Changes - Sales in the Americas grew by 8%, while Europe saw a 1% increase, and APAC experienced a 3% decline [8] - The company expanded its international sales footprint, particularly in Korea, which was the second-largest distribution market in 2021 [11] Company Strategy and Development Direction - The company plans to continue its focus on profitability and cash generation, as evidenced by the increase in dividends for the 11th consecutive year [13] - The company is actively pursuing acquisitions and has a share repurchase program to enhance shareholder value [28] Management's Comments on Operating Environment and Future Outlook - Management noted that the Omicron variant and staffing shortages impacted Q4 sales as hospitals deferred elective surgeries [8] - For Q1 2022, the company expects sales between $37.7 million and $39.7 million, representing an 8% increase at the midpoint compared to Q1 2021 [20] Other Important Information - The company ended Q4 2021 with no debt and $70 million in cash and investments, reflecting strong cash generation [19] - The company has been hiring to address supply chain issues and to ensure no back orders [10] Q&A Session Summary Question: Will there be any fundamental changes to the execution of the LeMaitre playbook? - Management indicated that there will be no changes to the playbook [25] Question: What was the market reaction to the recent price increase on Artegraft? - An 11% price increase was implemented in January, and the market reaction was positive [26] Question: Can you break out biologics versus non-biologics in the quarter? - Biologics were 48% of sales and increased by 10% [33] Question: How did valvulotomes perform in the quarter? - Valvulotomes had a good quarter, being one of the top three growth products [34] Question: What are the expectations for spending levels going forward? - Spending levels were higher due to hiring, and management expects this trend to taper off as the year progresses [35] Question: What is the expected number of sales reps by the end of 2022? - Management expects to reach between 115 and 120 sales reps by the end of 2022 [52]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10- Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to . Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-282545 ...

LeMaitre Vascular, Inc. Investor Presentation 1 Disclaimers Unaudited Quarterly Results This document contains quarterly financial results. Quarterly financial results are unaudited. Forward-Looking Statements This document contains certain forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve risks and uncertainties. Actual results and events may differ significantly from results and events described in forward-looking statements. Factors ...

LeMaitre Vascular, Inc. (NASDAQ:LMAT) Q3 2021 Earnings Conference Call October 28, 2021 5:00 PM ET Company Participants J.J. Pellegrino - Chief Financial Officer George LeMaitre - Chairman and Chief Executive Officer Dave Roberts - President Conference Call Participants Zachary Weiner - Jefferies Rick Wise - Stifel Javier Fonseca - Spartan Capital Brooks O’Neil - Lake Street Capital Mike Petusky - Barrington Research Scott Henry - ROTH Capital Anthony Petrone - Jefferies Operator Welcome to the LeMaitre Vas ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10- Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 Or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from Commission File Number 001-33092 LEMAITRE VASCULAR, INC. (Exact name of registrant as specified in its charter) Delaware 04-2825458 (State o ...

Financial Data and Key Metrics Changes - The company reported record Q2 sales of $40.7 million, representing a 64% increase compared to Q2 2020, with sales growth of 83% in the Americas, 36% in EMEA, and 30% in APAC [7] - Gross margin for Q2 2021 was 65.8%, a decrease of 2.7% year-over-year, attributed to product mix changes, manufacturing inefficiencies, and inventory write-downs [9] - Operating income was $11.1 million in Q2 2021, with an operating margin of 27% [10] - EBITDA for Q2 2021 was $13.3 million, up 108% year-over-year [10] - The company ended Q2 2021 with $23 million in debt and $21.8 million in cash and investments [10] - Full-year 2021 sales guidance is set at $154.1 to $158.1 million, indicating a 21% increase at the midpoint compared to 2020 [12] Business Line Data and Key Metrics Changes - Artegraft sales reached $6.7 million in Q2, contributing significantly to overall sales growth [8] - The company is expanding its product offerings, with notable sales from valvulotomes, carotid shunts, carotid patches, and allografts [8] Market Data and Key Metrics Changes - APAC market saw a boost from $250,000 in Japanese XenoSure sales, with expectations to submit trial results to the Chinese FDA by October [8] - The company plans to ship from warehouses to hospitals in 8 of its 9 largest markets by October [8] Company Strategy and Development Direction - The company is focused on rebuilding its sales force, aiming to return to a pre-COVID high of 112 sales reps, currently at 88 [8] - Expansion of warehouses in England, Italy, and Japan is underway to enhance customer connections and order fulfillment speed [8] - The management is considering larger acquisition targets, particularly in disposables and implantables used by vascular surgeons, while remaining open to branching into endovascular or cardiac surgery [20] Management's Comments on Operating Environment and Future Outlook - Management expressed cautious optimism regarding Q3, noting the potential impact of COVID-19 and seasonal trends on sales [16][18] - The company is experiencing a backlog of procedures that were delayed due to the pandemic, which contributed to strong Q2 performance [16] - There are concerns about the Delta variant affecting elective surgeries, particularly in the Southeast U.S. [24] Other Important Information - The company has paid down $42 million of debt since the Artegraft acquisition and recently retired the remaining $23 million with proceeds from a stock offering [11] - The management highlighted the importance of maintaining a clean balance sheet to attract potential sellers for acquisitions [20] Q&A Session Summary Question: Trends and momentum for Q3 - Management noted strong Q2 performance but expressed caution about Q3 due to potential seasonal slowdowns and COVID impacts [16] Question: Impact of hiring on manufacturing efficiencies - Management indicated that rehiring manufacturing personnel should improve efficiencies and margins in the coming quarters [18] Question: M&A pipeline and potential targets - The company is pursuing various acquisition targets, with a focus on larger opportunities in the vascular market [20] Question: Sales expectations for Q4 compared to Q2 - Management explained that Q2 was unique due to backlog recovery, and they are cautious about Q4 due to potential COVID impacts [24] Question: Hiring pace for sales force - Management acknowledged slow hiring progress but expects acceleration as they fill open positions [29] Question: Balance sheet status post-equity offering - Management confirmed a pro forma balance sheet with essentially zero debt and approximately $50 million in cash [33] Question: Artegraft's revenue compared to other product categories - Artegraft has surpassed some individual brands but has not yet overtaken the entire Valvulotomes category in revenue [39]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10- Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 Delaware 04-2825458 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) 63 Second Avenue, Burlington, Massachusetts 01803 (Address of principal executive offices) (Zip Code) (781) 221-2266 (Registrant's telephone num ...